Prognostic staging system "Barcelona Clinic Liver Cancer "and alpha-fetoprotein in hepatocellular carcinoma;Valor pronóstico del sistema de estadificación "Barcelona Clinic Liver Cancer" y la alfa-fetoproteína en el carcinoma hepatocelular

Revista Espanola de Enfermedades Digestivas

Volumn 104, Issue 6, 2012, Pages 298-304

  Rodríguez, Rafael Gómez ^a   Gutiérrez, Marta Romero ^a   Varasa, Tomás Artaza ^a   Frutos, Concepción González ^a   Dopazo, Juan José Ciampi ^a   Pérez, Gema de la Cruz ^a   Ruano, Juan José Sánchez ^a  

^a HOSPITAL VIRGEN DE LA SALUD   (Spain)

Author keywords

Alpha fetoprotein; BCLC staging; Hepatocellular carcinoma

Indexed keywords

ALPHA FETOPROTEIN; AFP PROTEIN, HUMAN;

ADULT; ARTICLE; BARCELONA CLINIC LIVER CANCER CLASSIFICATION; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER STAGING; FEMALE; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; AGED; BLOOD; CLINICAL TRIAL; FOLLOW UP; LIVER TUMOR; METABOLISM; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; SURVIVAL;

AGED; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84863308320     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: 10.4321/s1130-01082012000600003     Document Type: Article

References (44)

1. El-Serag HB, Lenhard Rudolph K. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-76.
2. Benvegnu L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 2004; 53:7449.
3. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127:S35-S50.
4. Bosetti C, Levi F, Boffetta P, Lucchini F, Negri E, La Vecchia C. Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004. Hepatology 2008;48:137-45.
5. Capocaccia R, Sant M, Berrino F, Simonetti A, Santi V, Trevisani F, et al. Hepatocellular carcinoma: trends of incidence and survival in Europe and the United States at the end of the 20th century. Am J Gastroenterol 2007;102:1-10.
6. Yu MC, Yuan JM. Environmental factors and risk for hepatocellular carcinoma. Gastroenterology 2004;127:S72-S78.
7. Bolondi L. Screening for hepatocellular carcinoma in cirrhosis. J Hepatol 2003;39:1076-84.
8. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004;130:417-22.
9. Sangiovanni A, Del Ninno E, Fasani P, de Fazio C, Ronchi G, Romeo R. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 2004;126:1005-14.
10. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-2.
11. Varela M, Reig M, de la Mata M, Matilla A, Bustamante J, Pascual S, et al. Treatment approach of hepatocellular carcinoma in Spain. Analysis of 705 patients from 62 centers. Med Clin (Barc) 2010;134:569-76.
12. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Seminar in Liver Disease 1999;19:329-38.
13. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002;35:519-24.
14. Cillo U, Vitale A, Grigoletto F, Farinati F, Brolese A, Zanus G, et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol 2006;44:723-31.
15. Trevisani F, Magini G, Santi V, Morselli-Labate AM, Cantarini M Ch, Di Nolfo MA, et al. Impact of etiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during surveillance. Am J Gastroenterol 2007;102:1022-31.
16. Yen YH, Changchien CS, Wang JH, Kee KM, Hung CH, Hu TH, et al. A modified TNM-based Japan Integrated Score combined with AFP level may serve as a better staging system for early-stage predominant hepatocellular carcinoma patients. Dig Dis 2009;41:431-41.
17. Peng SY, Chen WJ, Lai PL, Jeng YM, Sheu JC, Hsu HC. High fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and α-catenin mutations. Int J Cancer 2004;112:44-50.
18. Ravaioli M, Ercolani G, Cescon M, Vetrone G, Voci C, Grigioni WF, et al. Liver transplantation for hepatocellular carcinoma: further considerations on selection criteria. Liver Transplantation 2004;10:1195-202.
19. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001;35:421-40.
20. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36.
21. Nicolau C, Vilana R, Bianchi L, Bru C. Early-stage hepatocellular carcinoma: the high accuracy of real-time contrast-enhanced ultrasonography in the assessment of response to percutaneous tratment. Eur Radiol 2007;17(Supl. 6):F80-F88.
22. Cabibbo G, Enea m, Attanasio M, Bruix j, Craxi A, Gammà C. A metaanalysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology 2010;51:1274-83.
23. The Cancer of the Liver Italian Program (CLIP) Investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 1998;28:751-5.
24. Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso MC, Sala M, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999;29:62-7.
25. Cillo U, Bassanell M, Vitale A, Grigoletto A, Burra P. Fagiuoli S, et al. The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available? J Hepatol 2004;40:124-31.
26. Marrero JA, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, Su GL, et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 2005;41:707-16.
27. Kee K-M, Wang J-H, Lee Ch-M, Chen Ch-L, Changchien Ch-S, Hu T-H, et al. Validation of clinical AJCC/UICC TNM staging system for hepatocellular carcinoma: Analysis of 5,613 cases from a medical center in southern Taiwan. Int J Cancer 2007;120:2650-5.
28. Park KW, Park J-W, Choi J, Kim TH, Kim SH, Park HS, et al. Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus-endemic area. J Gastroen Hepatol 2007;23:467-73.
29. Changchien Ch-S, Chen Ch-L, Yen Y-H, Wang J-H, Hu T-H, Lee Ch-M, et al. Analysis of 6381 hepatocellular carcinoma patients in southern Taiwan: prognostic features, treatment outcome, and survival. J Gastroenterol 2008;43:159-70.
30. Tandon P, Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int 2009;29:502-10.
31. Schöinger-Hekele M, Müler C, Kutilek M, Oesterreicher C, Ferenci P, Gangl A. Hepatocellular carcinoma in Central Europe: prognostic features and survival. Gut 2001;48:103-9.
32. Kuo Y-H, Lu Sh-N, Chen Ch-L, Cheng Y-F, Lin Ch-Y, Hung Ch-H, et al. Hepatocellular carcinoma surveillance and appropriate treatment options improve survival for patients with liver cirrhosis. Eur J Cancer 2010;46:744-51.
33. Ueno Sh, Tanabe G, Nuruki K, Hamanoue M, Komorizono Y, Oketani M, et al. Prognostic performance of the new classification of primary liver cancer of Japan (4th edition) for patients with hepatocellular carcinoma: a validation analysis. Hepatol Res 2002;24:395-403.
34. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Gasegawa H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985;56:918-28.
35. Grieco A, Pompili M, Caminiti G, Miele L, Covino M, Alfei B, et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut 2005;54:411-8.
36. Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 2003;38:207-15.
37. Kudo M, Chung H, Haji S, Osaki Y, Oka H, Seki T, et al. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS Score compared with the CLIP Score-Hepatology 2004;40:1396-405.
38. Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, et al. Comparison of the usefulness of three staging systems for hepatocellular carcinoma (CLIP, BCLC, and JIS) in Japan. Am J Gastroenterol 2005;100:1764-71.
39. Farinati F, Marino D, De Giorgio M, Baldan A, Cantarini M, Cursaro C, et al. Diagnostic and prognostic role of α-fetoprotein in hepatocellular carcinoma: Both or Neither? Am J Gastroenterol 2006;101:524-32.
40. Cammà C, Di Marco V, Cabibbo G, Latteri F, Sandonato L, Parisi P, et al. Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems. Aliment Pharmacol Ther 2008;28:62-75.
41. Tangkijvanich P, Anukulkarnkusol N, Suwangool P, Lertmaharit S, Hanvivatvong O, Kullavanijaya P, et al. Clinical characteristics and prognosis of hepatocellular carcinoma. Analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol 2000;31:302-8.
42. Peng Sh-Y, Lai P-L, Chu J-Sh, Lee P-H, Tsung P-T, Chen D-Sh, et al. Expression and hypomethylation of alpha-fetoprotein gene in unicentric and multicentric human hepatocellular carcinoma. Hepatology 1993;17:35 41.
43. Lencioni R, Bartolozzi C, Caramella D, Paolicchi A, Carrai M, Maltini G, et al. Treatment of small hepatocellular carcinoma with percutaneous ethanol injection. Cancer 1995;76:1737-46.
44. Huo T-I, Huang Y-H, Lin H-Ch, Wu J-Ch, Chiang J-H, Lee P-Ch, et al. Proposal of a modified cancer of the liver italian program staging system based on the model for end-stage liver disease for patients with hepatocellular carcinoma undergoing loco-regional therapy. Am J Gastroenterol 2006;101:975-82.